DAVID MOLITERNO, University of Kentucky, Lexington
REFERENCE: American College of Cardiolgy New Orleans, March 24th Late Breaking Trials
An oral thrombin receptor antagonist, SCH 530348 has proved safe and effective, and may be better than conventional anti-coagulation treatments for patients receiving percutaneous coronary intervention. Results of the TRA-PCI study were presented at the ACC’s New Orleans meeting by David Moliterno who discussed the new data with Peter Goodwin.
An oral thrombin receptor antagonist, SCH 530348 has proved safe and effective, and may be better than conventional anti-coagulation treatments for patients receiving percutaneous coronary intervention. Results of the TRA-PCI study were presented at the ACC’s New Orleans meeting by David Moliterno who discussed the new data with Peter Goodwin.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.